Canakinumab vs Placebo (RCT)

Hospitalized patients

On Jan 26th, 2022, we published results of the Are medicines that block interleukin‐1 (a protein involved in immune responses) effective treatments for COVID‐19 and do they cause unwanted effects? which included all preprints and published trials published online up to November 5, 2021.

Studies included but not extracted/included in the analysis: Hepprich M, EClinicalMedicine, 2022

FOREST PLOTS -2022-10-07

Studies description

Trial NCT04362813; EudraCT 2020-001370-30
Publication CAN-COVID - Caricchio R, JAMA (2021) (published paper)
Dates: 2020-04-30 to 2020-08-17
Funding: Private (Novartis Pharma AG )
Conflict of interest: Yes

Trial NCT04365153
Publication The three C study - Cremer P, Eur Heart J (2021) (published paper)
Dates: 2020-04-28 to 2020-08-25
Funding: Private (Novartis )
Conflict of interest: No